Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences Inc (NASDAQ: PLSE) pioneers bioelectric medicine through its proprietary Nano-Pulse Stimulation technology, offering investors and medical professionals a novel approach to non-thermal therapies. This dedicated news hub provides real-time updates on clinical advancements, regulatory developments, and strategic partnerships shaping the future of targeted cellular treatments.
Access verified information about PLSE's progress in immuno-oncology applications, dermatology research breakthroughs, and system commercialization efforts. Our curated feed includes earnings reports, FDA submissions, peer-reviewed study results, and executive commentary – all essential for evaluating the company's position in the electroceuticals market.
Key updates cover therapeutic trial milestones, intellectual property expansions, and collaborations with leading medical institutions. Bookmark this page to monitor how PLSE's drug-free energy modalities could transform treatment protocols for complex conditions while driving long-term value in the medical device sector.
Pulse Biosciences, Inc. (NASDAQ: PLSE) announced its participation in the Stephens Annual Investment Conference in Nashville, Tennessee, scheduled for December 2, 2021. Management will engage in a fireside chat at 2:00 PM PT / 4:00 PM CT. Interested individuals can access the live and recorded webcast via the company’s website.
Pulse Biosciences specializes in bioelectric medicine, leveraging its CellFX® System and Nano-Pulse Stimulation™ technology to improve dermatologic outcomes.
Pulse Biosciences, Inc. (Nasdaq: PLSE) announced its third quarter 2021 financial results, reporting revenue of $574,000, with 12 Controlled Launch Program participants opting to acquire CellFX Systems for commercial use. The company onboarded a total of 68 participants and completed patient enrollment for key clinical studies. Operating expenses increased to $14.1 million, with a GAAP net loss of $14.3 million. Cash reserves totaled $42 million as of September 30, 2021. The company aims to expand the CellFX System's applications beyond dermatology.
Pulse Biosciences, Inc. (NASDAQ: PLSE) announced its participation in the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 1:40 pm PT / 4:40 pm ET. The company, known for its innovative bioelectric medicine, aims to enhance patient care through its CellFX® System and Nano-Pulse Stimulation™ (NPS™) technology. The CellFX System treats dermatologic conditions effectively while preserving surrounding tissue. Interested parties can access the on-demand webcast via the Company’s website.
Pulse Biosciences, Inc. (NASDAQ: PLSE) will release its financial results for Q3 2021 on November 15, 2021, after market close. A conference call is scheduled at 1:30 PM PT for investors to discuss the results. The company is known for its innovative Nano-Pulse Stimulation™ (NPS™) technology, with its first commercial product, the CellFX® System, addressing dermatologic conditions. The system offers a multi-application platform with a utilization-based revenue model, aiming to enhance patient care and outcomes.
Pulse Biosciences, Inc. (NASDAQ: PLSE) announced the appointment of Laureen DeBuono to its Board of Directors, succeeding Kenneth Clark, who has resigned. DeBuono brings extensive executive experience in driving growth and shareholder value in life sciences and medical technology sectors. She has previously held positions at Rodan+Fields and served as CEO of govino, LLC. Her appointment aims to enhance the commercial growth of the CellFX® System in dermatology and expand the company’s multi-specialty bioelectric medicine profile.
Pulse Biosciences (NASDAQ: PLSE) announces its participation in the H.C. Wainwright Global Investment Conference on September 14, 2021. Management will hold one-on-one meetings and the event will feature a presentation webcast available starting on September 13, 2021, at 7:00 am ET. The company's CellFX® System, utilizing Nano-Pulse Stimulation™ technology, aims to improve dermatologic outcomes by treating various conditions while preserving adjacent non-cellular tissue. More information can be found on CellFX.com.
Pulse Biosciences (Nasdaq: PLSE) announces the appointment of Mitchell E. Levinson as the new Chief Strategy Officer, alongside his existing position on the board. Levinson, a veteran in the medical device industry with over 30 years of experience, aims to drive the company's expansion into multiple specialties, leveraging the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology. This strategic move is expected to enhance the company's dermatology business and facilitate broader applications of NPS technology, addressing unmet healthcare needs.
Pulse Biosciences (PLSE) reported its Q2 2021 financial results, highlighting significant developments in its CellFX System's launch and clinical trials. By the end of Q2, 49 clinics participated in the Controlled Launch Program, with 34 onboarded in that quarter. The company achieved Health Canada approval and initiated Canadian operations. Financially, cash reserves decreased to $47.4 million, with a net loss of $15.3 million. Non-GAAP operating expenses rose to $12.1 million, driven by increased commercialization efforts.
Pulse Biosciences (Nasdaq: PLSE) will release its financial results for Q2 2021 after market close on August 9, 2021. A conference call led by management will follow at 1:30 PM PT. The company focuses on Nano-Pulse Stimulation™ (NPS™) technology, with its CellFX® System being the first commercial product designed for dermatologic applications, allowing for the non-thermal treatment of cells while preserving surrounding tissue. This multi-application platform adopts a utilization-based revenue model, intending to elevate patient outcomes.
Pulse Biosciences (Nasdaq: PLSE) has entered a stock purchase agreement with Robert W. Duggan for 3,048,780 shares at $16.40 each. This deal will clear $41.6 million in debt owed to Duggan, who will invest an additional $8.4 million. Following this transaction, Duggan's ownership will rise to 51% of the company, making it a controlled entity. The funds will support the CellFX System Controlled Launch Program and expand clinical applications for Nano-Pulse Stimulation technology. The closing is expected by July 7, 2021.
